Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension

安慰剂 随机化 利尿剂 临床终点 置信区间 医学 收缩期高血压 随机对照试验 醛固酮 内科学 血压 病理 替代医学
作者
John M. Flack,Michel Azizi,Jenifer Michelle Brown,Jamie P. Dwyer,Jakub Fronczek,Erika S W Jones,Daniel S Olsson,Shira Perl,Hirotaka Shibata,Jiguang Wang,Ulrica Wilderäng,Janet Turk Wittes,Bryan Williams
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:393 (14): 1363-1374 被引量:199
标识
DOI:10.1056/nejmoa2507109
摘要

BACKGROUND: Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood pressure of patients with uncontrolled or resistant hypertension. METHODS: In this phase 3, multinational, double-blind, randomized, placebo-controlled trial, we recruited patients with a seated systolic blood pressure of between 140 mm Hg and less than 170 mm Hg despite the receipt of stable treatment with two antihypertensive medications (uncontrolled hypertension) or three or more such medications (resistant hypertension), including a diuretic. After a 2-week placebo run-in period, we randomly assigned patients with a seated systolic blood pressure of 135 mm Hg or more in a 1:1:1 ratio to receive baxdrostat at a dose of 1 mg, baxdrostat at a dose of 2 mg, or placebo once daily for 12 weeks. The primary end point was the change in seated systolic blood pressure from baseline to week 12. RESULTS: A total of 796 patients underwent randomization and 794 received 1-mg baxdrostat (264 patients), 2-mg baxdrostat (266 patients), or placebo (264 patients) in addition to background therapy. At 12 weeks, the change from baseline in the least-squares mean seated systolic blood pressure was -14.5 mm Hg (95% confidence interval [CI], -16.5 to -12.5) with 1-mg baxdrostat, -15.7 mm Hg (95% CI, -17.6 to -13.7) with 2-mg baxdrostat, and -5.8 mm Hg (95% CI, -7.9 to -3.8) with placebo. The estimated difference from placebo (placebo-corrected difference) was -8.7 mm Hg (95% CI, -11.5 to -5.8) with 1-mg baxdrostat and -9.8 mm Hg (95% CI, -12.6 to -7.0) with 2-mg baxdrostat (P<0.001 for both comparisons). A potassium level of more than 6.0 mmol per liter was reported in 6 patients (2.3%) with 1-mg baxdrostat, in 8 patients (3.0%) with 2-mg baxdrostat, and in 1 patient (0.4%) with placebo. CONCLUSIONS: Among patients with uncontrolled or resistant hypertension, the addition of baxdrostat to background therapy resulted in a significantly lower seated systolic blood pressure at 12 weeks than placebo. (Funded by AstraZeneca and others; BaxHTN ClinicalTrials.gov number, NCT06034743.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
smile完成签到,获得积分20
刚刚
刚刚
可爱的函函的应助被beyfish采纳,获得10
1秒前
希望天下0贩的0的应助被Lucky采纳,获得30
1秒前
JJJ发布了新的文献求助10
2秒前
科目三的应助被Wissenheimer采纳,获得10
2秒前
wu完成签到 ,获得积分10
2秒前
3秒前
犯困完成签到,获得积分10
4秒前
4秒前
5秒前
哇哈哈哈发布了新的文献求助10
5秒前
NexusExplorer的应助被原长卿采纳,获得10
6秒前
充电宝的应助被Doraemon-2077采纳,获得10
6秒前
领导范儿的应助被酱油采纳,获得10
6秒前
zzy发布了新的文献求助10
7秒前
7秒前
耍酷雨发布了新的文献求助30
7秒前
真王一博发布了新的文献求助30
8秒前
祝盟完成签到 ,获得积分10
8秒前
转转发布了新的文献求助10
8秒前
9秒前
虚心十三完成签到,获得积分10
9秒前
9秒前
Viiv完成签到,获得积分10
9秒前
10秒前
小北完成签到 ,获得积分10
10秒前
尹有创发布了新的文献求助10
10秒前
gjy发布了新的文献求助10
11秒前
mlppp完成签到,获得积分20
11秒前
科研通AI65的应助被嘻嘻嘻采纳,获得10
11秒前
12秒前
虚心十三发布了新的文献求助10
12秒前
欣慰的天抒完成签到,获得积分20
12秒前
samuel完成签到,获得积分10
12秒前
star完成签到 ,获得积分10
13秒前
13秒前
汉堡国王发布了新的文献求助10
13秒前
眼睛大的冰珍完成签到,获得积分10
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189472
求助须知:如何正确求助?哪些是违规求助? 9576774
关于积分的说明 21849709
捐赠科研通 7787422
什么是DOI,文献DOI怎么找? 3435600
关于科研通互助平台的介绍 2559782
邀请新用户注册赠送积分活动 2482552